CRISPR Therapeutics AG (CRSP) Key Metrics
CRSP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $4.76B
- Enterprise value
- $3.81B
- P/E (TTM)
- —
- Forward P/E
- 23.4
- PEG ratio
- —
- Price / sales
- 355.6 10-yr median 18.2
- Price / book
- 3.1 10-yr median 2.6
- EV / EBITDA
- 14.2
- Dividend yield
- —
- Beta
- 1.76
CRSP key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCRSP valuation Price multiples at each fiscal year-end price.
Price / book+42.8%
2.5
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−3.0 pts
−7.3%
2025 · hover or tap a bar for each year
20162025
CRSP returns How much profit the business earns on the capital it uses.
Return on equity−11.0 pts
−30.2%
2025 · hover or tap a bar for each year
20162025
Return on invested capital−43.0 pts
−151.5%
2025 · hover or tap a bar for each year
20162025
Return on assets−9.4 pts
−25.8%
2025 · hover or tap a bar for each year
20162025
Asset turnover−90.1%
0.00
2025 · hover or tap a bar for each year
20162025
CRSP per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−90.6%
$0.04
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$6.47
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$3.85
2025 · hover or tap a bar for each year
20162025
Book value per share−6.7%
$21.37
2025 · hover or tap a bar for each year
20162025
Shares outstanding+6.6%
89.9M
2025 · hover or tap a bar for each year
20162025
CRSP financial health Debt, liquidity and how easily interest is covered.
Debt / equity+77.5%
0.21
2025 · hover or tap a bar for each year
20162025
Net debt+$99.2M
−$1.58B
2025 · hover or tap a bar for each year
20162025
Current ratio−39.7%
13.32
2025 · hover or tap a bar for each year
20162025
Debt / assets+74.7%
0.17
2025 · hover or tap a bar for each year
20162025
CRSP efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+127 days
1,300 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding−67 days
20 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle+194 days
1,280 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+20.6 pts
26.0%
2025 · hover or tap a bar for each year
20162025
CRSP valuation history
Fiscal year-endToday10-year median
CRSP returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CRSP debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CRSP cash returned to shareholders
DividendsBuybacksFree cash flow
CRSP price vs earnings per share
Share price at year-endEPS (right axis)
CRSP key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.72B | $3.32B | $4.96B | $3.16B | $6.09B | $10.10B | $3.47B | $1.37B | $940.5M | — |
| Enterprise value | $3.13B | $1.64B | $3.50B | $1.59B | $3.94B | $8.47B | $2.58B | $949.0M | $745.0M | — |
| P/E ratio | — | — | — | — | 16.1 | — | 51.9 | — | — | — |
| Price / sales | — | 94.9 | 13.4 | — | 6.7 | — | 12.0 | 438.6 | 22.9 | — |
| Price / book | 2.5 | 1.7 | 2.6 | 1.7 | 2.5 | 6.1 | 3.7 | 3.5 | 5.0 | — |
| Price / free cash flow | — | — | — | — | 13.3 | — | 69.4 | — | — | — |
| Price / operating cash flow | — | — | — | — | 11.3 | — | 61.2 | — | — | — |
| EV / sales | 893.1 | 46.9 | 9.5 | — | 4.3 | — | 8.9 | 303.8 | 18.2 | — |
| EV / EBITDA | — | — | — | — | 10.1 | — | 50.1 | — | — | — |
| EV / free cash flow | — | — | — | — | 8.6 | — | 51.5 | — | — | — |
| Earnings yield | −12.3% | −11.0% | −3.1% | −20.6% | 6.2% | −3.5% | 1.9% | −12.0% | −7.3% | — |
| Free cash flow yield | −7.3% | −4.4% | −5.4% | −16.9% | 7.5% | −2.5% | 1.4% | −7.2% | −8.3% | — |
| Dividend yield | — | — | — | — | — | — | — | — | 0.0% | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $52.44 | $39.36 | $62.60 | $40.65 | $75.78 | $153.11 | $60.91 | $28.57 | $23.48 | $20.26 |
| Per share | ||||||||||
| Revenue per share | $0.04 | $0.41 | $4.67 | $0.01 | $11.36 | $0.01 | $5.09 | $0.07 | $1.02 | — |
| Earnings per share | −$6.47 | −$4.34 | −$1.94 | −$8.36 | $4.70 | −$5.29 | $1.17 | −$3.44 | −$1.71 | — |
| Operating cash flow per share | −$3.84 | −$1.69 | −$3.29 | −$6.38 | $6.70 | −$3.61 | $1.00 | −$2.01 | −$1.75 | — |
| Free cash flow per share | −$3.85 | −$1.71 | −$3.41 | −$6.85 | $5.69 | −$3.89 | $0.88 | −$2.06 | −$1.94 | — |
| Cash per share | $21.97 | $22.57 | $21.38 | $23.35 | $29.59 | $25.63 | $16.58 | $9.52 | $5.99 | — |
| Book value per share | $21.37 | $22.90 | $23.77 | $24.12 | $29.85 | $25.23 | $16.50 | $8.18 | $4.69 | — |
| Tangible book value per share | $21.37 | $22.90 | $23.77 | $24.12 | $29.84 | $25.23 | $16.50 | $8.17 | $4.68 | — |
| Dividends per share | — | — | — | — | — | — | — | — | $0.00 | — |
| Capex per share | $0.01 | $0.02 | $0.12 | $0.48 | $1.02 | $0.28 | $0.12 | $0.06 | $0.20 | — |
| Debt per share | $4.39 | $2.65 | $3.01 | $3.14 | $2.80 | $0.93 | $0.92 | $0.74 | $1.10 | — |
| Shares outstanding | 89.9M | 84.4M | 79.2M | 77.7M | 80.4M | 65.9M | 56.9M | 48.0M | 40.1M | — |
| Change in shares outstanding | +6.6% | +6.5% | +1.9% | −3.3% | +21.9% | +15.8% | +18.7% | +19.7% | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −30.2% | −19.2% | −8.2% | −30.4% | 18.6% | −26.8% | 10.0% | −56.9% | −32.5% | −22.8% |
| Return on invested capital (ROIC) | −151.5% | −108.5% | −48.0% | −193.5% | 264.8% | −670.5% | 487.1% | — | — | — |
| Return on assets (ROA) | −25.8% | −16.4% | −6.9% | −26.0% | 16.5% | −24.1% | 8.6% | −43.4% | −22.2% | −9.2% |
| Return on tangible assets | −25.7% | −16.3% | −6.9% | −29.0% | 13.7% | −19.1% | 6.3% | −33.8% | −25.2% | −6.7% |
| Free cash flow margin | — | −413.4% | −72.9% | — | 50.1% | — | 17.3% | — | −190.0% | — |
| Income quality (OCF / net income) | — | — | — | — | 1.43 | — | 0.85 | — | — | — |
| Financial health | ||||||||||
| Total debt | $394.9M | $223.7M | $238.6M | $244.0M | $225.0M | $61.4M | $52.5M | $35.3M | $44.2M | $60.3M |
| Cash & short-term investments | $1.98B | $1.90B | $1.69B | $1.82B | $2.38B | $1.69B | $943.8M | $456.6M | $239.8M | $315.5M |
| Net debt | −$1.58B | −$1.68B | −$1.46B | −$1.57B | −$2.15B | −$1.63B | −$891.2M | −$421.3M | −$195.6M | −$255.2M |
| Debt / equity | 0.21 | 0.12 | 0.13 | 0.13 | 0.09 | 0.04 | 0.06 | 0.09 | 0.24 | 0.26 |
| Debt / assets | 0.17 | 0.10 | 0.11 | 0.11 | 0.08 | 0.03 | 0.05 | 0.07 | 0.16 | 0.17 |
| Net debt / EBITDA | — | — | — | — | −5.50 | — | −17.32 | — | — | — |
| Current ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Quick ratio | 13.32 | 22.07 | 17.54 | 15.39 | 20.17 | 18.21 | 17.29 | 16.81 | 17.12 | 14.56 |
| Interest coverage | — | — | — | -14.4 | 15.6 | -55.6 | 1.8 | — | — | -8.5 |
| Working capital | $1.84B | $1.85B | $1.80B | $1.73B | $2.30B | $1.62B | $930.4M | $438.6M | $233.9M | $298.2M |
| Invested capital | $340.9M | $251.9M | $427.7M | $304.2M | $245.4M | $35.3M | $48.2M | −$29.1M | −$7.7M | −$22.4M |
| Tangible asset value | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.2M | $391.9M | $187.5M | $232.4M |
| Net current asset value | $1.64B | $1.63B | $1.56B | $1.49B | $2.07B | $1.55B | $860.2M | $369.6M | $164.9M | $208.1M |
| Graham number | — | — | — | — | $56.17 | — | $20.88 | — | — | — |
| Graham net-net per share | $18.15 | $19.12 | $18.90 | $18.66 | $25.21 | $23.27 | $14.34 | $7.50 | $3.95 | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | $0 | — | — | $0 | $0 | $0 | $0 | $57,000 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | 0.0% | — | 0.0% | — | — | — |
| Capex / revenue | 26.0% | 5.4% | 2.6% | 8,529.4% | 8.9% | 2,553.3% | 2.3% | 88.8% | 19.1% | 58.4% |
| Capex / operating cash flow | — | — | — | — | 15.2% | — | 11.8% | — | — | — |
| Capex / depreciation | 0.05 | 0.10 | 0.48 | 1.54 | 4.55 | 2.00 | 1.41 | 0.79 | 2.58 | 3.26 |
| Stock-based compensation / revenue | 2,065.5% | 247.3% | 21.9% | 22,464.9% | 11.2% | 9,181.9% | 15.2% | 1,119.9% | 46.0% | 210.0% |
| R&D / revenue | 7,559.2% | 916.2% | 104.7% | 105,881.9% | 48.0% | 30,790.3% | 61.9% | 3,641.9% | 170.3% | 817.9% |
| SG&A / revenue | 2,095.2% | 208.5% | 20.6% | 23,500.9% | 11.3% | 11,925.9% | 21.9% | 1,545.9% | 87.4% | 601.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 1,299.9 | 1,173.2 | 104.2 | 4,815.7 | 2.2 | 2,777.6 | 0.1 | 158.5 | 25.7 | 123.6 |
| Days of inventory on hand | — | — | — | -37.1 | — | — | 0.0 | 0.0 | 0.0 | — |
| Days payables outstanding | 20.2 | 87.5 | 91.9 | 69.9 | 43.1 | 10.2 | 11.2 | 10.8 | 16.2 | 26.6 |
| Cash conversion cycle (days) | 1,279.6 | 1,085.7 | 12.3 | 4,708.7 | -40.9 | 2,767.4 | -11.1 | 147.8 | 9.5 | 97.0 |
| Receivables turnover | 0.28 | 0.31 | 3.50 | 0.08 | 163.80 | 0.13 | 3,097.22 | 2.30 | 14.18 | 2.95 |
| Payables turnover | 18.03 | 4.17 | 3.97 | 5.22 | 8.46 | 35.83 | 32.57 | 33.92 | 22.49 | 13.73 |
| Inventory turnover | — | — | — | — | — | — | 179,362,000.00 | 113,773,000.00 | 139,600,000.00 | — |
| Asset turnover | 0.00 | 0.02 | 0.17 | 0.00 | 0.40 | 0.00 | 0.37 | 0.01 | 0.13 | 0.02 |
| Average receivables | $12.5M | $112.5M | $105.6M | $5.8M | $5.6M | $5.5M | $93,500 | $1.4M | $2.9M | $1.7M |
| Average payables | $12.9M | $26.4M | $32.8M | $21.1M | $12.0M | $7.5M | $5.5M | $3.4M | $3.1M | $3.1M |
| Average inventory | — | — | — | −$11.2M | — | — | $1 | $1 | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% |
Computed from CRSP's annual financial statements (latest annual report filed February 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CRSP valuation and financial ratios
CRISPR Therapeutics earned a return on equity of −30.2% and a return on invested capital of −151.5% in fiscal 2025. It ended the year with $394.9 million of debt and $2.0 billion in cash and short-term investments, a net cash position of $1.6 billion.
See the CRSP income statement, the CRSP chart for price history, or the CRSP stock overview for the latest quote and news.
CRSP key metrics FAQ
What is CRISPR Therapeutics's return on equity?
CRISPR Therapeutics's return on equity (ROE) was −30.2% in fiscal 2025: net income of -$581.6 million on average shareholders' equity of $1.9 billion.
What is CRISPR Therapeutics's ROIC?
CRISPR Therapeutics's return on invested capital was −151.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does CRISPR Therapeutics have?
CRISPR Therapeutics had total debt of $394.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.21 and more cash than debt.
What is CRISPR Therapeutics's free cash flow yield?
CRISPR Therapeutics generated -$345.9 million of free cash flow in fiscal 2025, a free cash flow yield of −7.3% on its market value at year-end ($4.7 billion).
What is CRISPR Therapeutics's current ratio?
CRISPR Therapeutics's current ratio was 13.32 at the end of fiscal 2025: current assets were 13.32 times current liabilities.